24 December 2024NewsAmericasMuireann Bolger

Fed Circ orders Teva to delist five patents from Orange Book

Dispute stems from Amneal’s efforts to market generic version of Teva’s inhaler for treating asthma | Precedential decision could restrict how brand-name pharmaceutical companies use the Orange Book to extend market exclusivity.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Teva secures stay on Orange Book inhaler patent delisting

18 June 2024 New Jersey court grants 30-day stay days after ordering the removal of five patents for asthma inhalers from FDA Orange Book | Decision follows ruling favouring Amneal Pharmaceuticals, which argued the patents were improperly listed.

Americas

Teva fights for re-listing of inhaler patents at US appeals court

12 November 2024 Oral arguments heard in case between Teva and generics maker Amneal over inhaler patents | Teva says district court and Amneal asked court to ‘slice apart new drug application’.

Americas

Teva asks Fed Circ to reverse inhaler patents loss

1 August 2024 Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed.

More on this story

Big Pharma

Teva secures stay on Orange Book inhaler patent delisting

Americas

Teva fights for re-listing of inhaler patents at US appeals court

12 November 2024 Oral arguments heard in case between Teva and generics maker Amneal over inhaler patents | Teva says district court and Amneal asked court to ‘slice apart new drug application’.

Americas

Teva asks Fed Circ to reverse inhaler patents loss

More on this story

Big Pharma

Teva secures stay on Orange Book inhaler patent delisting

Americas

Teva fights for re-listing of inhaler patents at US appeals court

12 November 2024 Oral arguments heard in case between Teva and generics maker Amneal over inhaler patents | Teva says district court and Amneal asked court to ‘slice apart new drug application’.

Americas

Teva asks Fed Circ to reverse inhaler patents loss